GBM

  •  

    Learnings from Pilot Study: Creating Treatment Templates to Serve More Glioblastoma Patients

    With: Adrienne Nugent, PhD

    A recent pilot study between Cancer Commons and the Musella Foundation for Brain Tumor Research & Information is identifying patterns that are being translated into treatment templates to better serve a larger group of GBM patients. Our Curious Dr. George asks Cancer Commons Scientist Adrienne Nugent, PhD, to discuss key factors that point to the best courses of action a patient might take, and about the clinical… Read more »

  •  

    Using Virtual Trials to Screen for Potential Glioblastoma Therapies

    With: Al Musella, DPM

    The existing drug development system “has failed miserably” for people with glioblastoma brain tumors, according to Al Musella, DPM, President of the Musella Foundation for Brain Tumor Research & Information, Inc. In partnership with Cancer Commons, his organization’s Brain Tumor Virtual Trial aims to speed discovery of promising new glioblastoma treatments. Curious Dr. George: How might your Virtual Trial approach speed the process toward… Read more »

  •  

    When is the Best Time to Seek a Clinical Trial for Glioblastoma?

    With: Eric Wong, MD

    For some people with glioblastoma brain tumors, enrolling in a clinical trial enables access to cutting-edge treatment. Here, our Curious Dr. George talks clinical trials with Cancer Commons Expert Physician Advisor, Eric T. Wong, MD. Dr. Wong is also Associate Professor of Neurology at Harvard Medical School and Co-Director of the Brain Tumor Center at Beth Israel Deaconess Medical Center. Curious Dr. George: Malignant… Read more »

  •  

    How an Expert Would Treat His Own Glioblastoma

    With: Al Musella, DPM

    Two years ago, our Curious Dr. George asked Al Musella, DPM, what he would do if he were diagnosed with glioblastoma multiforme (GBM). Here, he revisits that question. Dr. Musella is President of the Musella Foundation For Brain Tumor Research & Information, Inc. Curious Dr. George: You direct an established foundation that supports research and information about brain tumors. What would you do if… Read more »

  •   George Lundberg, MD

    Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    In a phase 2 clinical trial, glioblastoma patients were treated with a herpes virus that has been genetically engineered to kill cancer cells. The genetically engineered virus is injected directly into patients’ brain tumors. It is early and the numbers are small, but the trial produced amazing results compared to historical controls.

    Go to full paper published in Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from WKYC Studios curated by Editor in Chief George Lundberg, MD, who notes: 

    An experimental treatment in which the virus that causes polio is directly injected into glioblastoma (GBM) tissue has shown some promise, as reported in the New England Journal of Medicine in 2018. This news story from WKYC provides a partial update from an ongoing subsequent clinical trial.

    Go to full article published by WKYC Studios.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Press release from Novocure curated by Editor in Chief George Lundberg, MD, who notes: 

    Chinese doctors managing one the most difficult tumors to treat, glioblastoma (GBM), now have another approved option, Optune, after favorable clinical trial results. The method has been previously approved by the U.S. Food and Drug Administration.

    Go to full article published by Novocure on Business Wire.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from The Pathologist curated by Editor in Chief George Lundberg, MD, who notes: 

    Liquid biopsy shows surprising apparent prognostic value in glioblastoma multiforme (GBM).

    Go to full article published by The Pathologist.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    A large, retrospective study demonstrates that surgical removal of as much tumor tissue as possible results in the best outcomes for patients—seems pretty logical, and is true.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.